DPP4 Is a Potential Prognostic Marker of Thyroid Carcinoma and a Target for Immunotherapy

Figure 1

The differential expression of DPP4 and its effect on prognosis in THCA. (a) The analysis result from TIMER: the mRNA expression level of DPP4 in THCA is statistically higher than that in normal thyroid tissues (). (b) The result from GEPIA is consistent with that of A (). (c) Expression of DPP4 at the mRNA level in 7 different pathological types of thyroid nodules (). (d) DPP4 expression significantly affects DFS of THCA patients (). (e) DPP4 expression is different in patients with different clinical stages of THCA, Stage 2 vs. Stage 3 (), and Stage 2 vs. Stage 4 (). (f) DPP4 expression is different in THCA patients with different lymph node metastatic status, N0 vs N1 (). (g) DPP4 expression is different in different age groups of THCA patients, Age (21–40 Years) vs. Age (41–60 Years) (), and Age (21–40 Years) vs. Age (61–80 Years) (). (h) There are differences in DPP4 expression among THCA patients with different histological subtypes, CPTC vs. TPTC (), CPTC vs. FPTC (), and TPTC vs. FPTC ().

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)